全文获取类型
收费全文 | 14248篇 |
免费 | 690篇 |
国内免费 | 84篇 |
专业分类
耳鼻咽喉 | 157篇 |
儿科学 | 276篇 |
妇产科学 | 218篇 |
基础医学 | 1797篇 |
口腔科学 | 321篇 |
临床医学 | 885篇 |
内科学 | 3615篇 |
皮肤病学 | 169篇 |
神经病学 | 1079篇 |
特种医学 | 560篇 |
外科学 | 2514篇 |
综合类 | 81篇 |
一般理论 | 1篇 |
预防医学 | 432篇 |
眼科学 | 358篇 |
药学 | 877篇 |
中国医学 | 25篇 |
肿瘤学 | 1657篇 |
出版年
2023年 | 84篇 |
2022年 | 61篇 |
2021年 | 237篇 |
2020年 | 160篇 |
2019年 | 199篇 |
2018年 | 280篇 |
2017年 | 239篇 |
2016年 | 289篇 |
2015年 | 267篇 |
2014年 | 368篇 |
2013年 | 407篇 |
2012年 | 664篇 |
2011年 | 769篇 |
2010年 | 475篇 |
2009年 | 395篇 |
2008年 | 612篇 |
2007年 | 701篇 |
2006年 | 724篇 |
2005年 | 735篇 |
2004年 | 741篇 |
2003年 | 690篇 |
2002年 | 667篇 |
2001年 | 413篇 |
2000年 | 405篇 |
1999年 | 348篇 |
1998年 | 180篇 |
1997年 | 148篇 |
1996年 | 115篇 |
1995年 | 137篇 |
1994年 | 125篇 |
1993年 | 146篇 |
1992年 | 307篇 |
1991年 | 256篇 |
1990年 | 254篇 |
1989年 | 288篇 |
1988年 | 227篇 |
1987年 | 231篇 |
1986年 | 216篇 |
1985年 | 211篇 |
1984年 | 155篇 |
1983年 | 134篇 |
1982年 | 53篇 |
1981年 | 56篇 |
1980年 | 65篇 |
1979年 | 106篇 |
1978年 | 81篇 |
1977年 | 76篇 |
1975年 | 48篇 |
1974年 | 50篇 |
1968年 | 50篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
1.
2.
3.
Mamiko Onuki Koji Matsumoto Takashi Iwata Kasumi Yamamoto Yoichi Aoki Shoji Maenohara Naotake Tsuda Shoji Kamiura Kazuhiro Takehara Koji Horie Nobutaka Tasaka Hideaki Yahata Yuji Takei Yoichi Aoki Hisamori Kato Takeshi Motohara Keiichiro Nakamura Mitsuya Ishikawa Tatsuya Kato Hiroyuki Yoshida Noriomi Matsumura Hidekatsu Nakai Shogo Shigeta Fumiaki Takahashi Kiichiro Noda Nobuo Yaegashi Hiroyuki Yoshikawa 《Cancer science》2020,111(7):2546-2557
To obtain baseline data for cervical cancer prevention in Japan, we analyzed human papillomavirus (HPV) data from 5045 Japanese women aged less than 40 years and diagnosed with cervical abnormalities at 21 hospitals during 2012‐2017. These included cervical intraepithelial neoplasia grade 1 (CIN1, n = 573), CIN2‐3 (n = 3219), adenocarcinoma in situ (AIS, n = 123), and invasive cervical cancer (ICC, n = 1130). The Roche Linear Array was used for HPV genotyping. The HPV type‐specific relative contributions (RCs) were estimated by adding multiple infections to single types in accordance with proportional weighting attributions. Based on the comparison of type‐specific RCs between CIN1 and CIN2‐3/AIS/ICC (CIN2+), RC ratios were calculated to estimate type‐specific risks for progression to CIN2+. Human papillomavirus DNA was detected in 85.5% of CIN1, 95.7% of CIN2‐3/AIS, and 91.2% of ICC. Multiple infections decreased with disease severity: 42.9% in CIN1, 40.4% in CIN2‐3/AIS, and 23.7% in ICC (P < .0001). The relative risk for progression to CIN2+ was highest for HPV16 (RC ratio 3.78, 95% confidence interval [CI] 3.01‐4.98), followed by HPV31 (2.51, 1.54‐5.24), HPV18 (2.43, 1.59‐4.32), HPV35 (1.56, 0.43‐8.36), HPV33 (1.01, 0.49‐3.31), HPV52 (0.99, 0.76‐1.33), and HPV58 (0.97, 0.75‐1.32). The relative risk of disease progression was 1.87 (95% CI, 1.71‐2.05) for HPV16/18/31/33/35/45/52/58, but only 0.17 (95% CI, 0.14‐0.22) for HPV39/51/56/59/66/68. Human papillomavirus 16/18/31/33/45/52/58/6/11 included in a 9‐valent vaccine contributed to 89.7% (95% CI, 88.7‐90.7) of CIN2‐3/AIS and 93.8% (95% CI, 92.4‐95.3) of ICC. In conclusion, our data support the Japanese guidelines that recommend discriminating HPV16/18/31/33/35/45/52/58 genotypes for CIN management. The 9‐valent vaccine is estimated to provide over 90% protection against ICC in young Japanese women. 相似文献
4.
Daisuke Yamamoto Kou Kayamori Kei Sakamoto Maiko Tsuchiya Tohru Ikeda Hiroyuki Harada Tetsuya Yoda Tetsuro Watabe Miki Hara‐Yokoyama 《Cancer science》2020,111(2):700-712
Claudins are the major component of tight junctions, which form a primary barrier to paracellular diffusion and maintain cell polarity in normal epithelia and endothelia. In cancer cells, claudins play additional roles besides serving as components of the tight junctions, and participate in anoikis or invasion. Among the claudin family proteins, claudin‐1 has the most promising potential, both diagnostically and prognostically, in many types of cancers, including oral, gastric, liver, and colon cancers. However, conflicting results have been reported in relation to the degree of claudin‐1 expression and the prognosis, suggesting that the expression level of claudin‐1 alone is not sufficient to analyze the relationship between claudin‐1 and cancer progression. As endocytic trafficking of claudin‐1 has been reported in several epithelial cell types in vitro, we aimed to determine whether intracellular localization of claudin‐1 is the missing aspect between claudin‐1 and cancer. We investigated the expression of claudin‐1 in 83 tongue squamous cell carcinoma (TSCC) pathological specimens. Although the expression level of claudin‐1 based on immunohistochemistry was not associated with TSCC progression, within the high claudin‐1 expression group, the incidence of intracellular localization of claudin‐1 was correlated with cervical lymph node metastasis. In an in vitro experiment, claudin‐1 was constitutively internalized in TSCC‐derived cells. Motility of TSCC‐derived cells was increased by deficiency of claudin‐1, suggesting that the decrease in cell‐surface claudin‐1 promoted the cell migration. Therefore, intracellular localization of claudin‐1 at the invasion front may represent a promising diagnostic marker of TSCC. 相似文献
5.
Hiroaki Soyama Morikazu Miyamoto Hiroko Matsuura Hideki Iwahashi Soichiro Kakimoto Hiroki Ishibashi Takahiro Sakamoto Taira Hada Jin Suminokura Masashi Takano 《Cancer chemotherapy and pharmacology》2020,85(5):941-947
The aim of this study was to investigate the association between changes in the levels of vascular endothelial growth factors (VEGFs) after treatment with bevacizumab and gemcitabine (Bev-Gem) and the clinical outcome. Platinum-resistant ovarian cancer patients treated with Bev-Gem therapy at our hospital between 2014 and 2018 were identified. Serum VEGF levels at the first and second treatment cycle were measured by ELISA. All patients were categorized into two groups—patients with > 50% decrease in serum VEGF-A levels (Group A) and patients with < 50% decrease serum VEGF-A levels (Group B). The association between clinical outcome and serum VEGF levels was investigated between the two groups. Among 18 patients, 10 were in Group A and 8 in Group B. Group A exhibited a lower response rate (0% vs.75% p < 0.01) and clinical benefit rate (60% vs.100% p = 0.02) than Group B. The median serum VEGF-A level of Group A before the first cycle of Bev-Gem therapy was higher than that in Group B (61.2 vs. 3.7 pg/mL, p < 0.01). Group A exhibited worse PFS (7 vs., 10 months, p < 0.01) and OS (17 vs. 26 months, p = 0.04) than Group B. There were more patients with > 10% increase in serum VEGF-B levels in Group A than in Group B (p < 0.01). The rapid decrease in VEGF-A levels and the resultant increase in serum VEGF-B levels might be associated with an unfavorable clinical outcome. Large-scale studies are needed to further examine these results. 相似文献
6.
7.
8.
9.